Gene delivery technologies company SIRION Biotech GmbH reported on Monday revenues of EUR3.1m for its vector design and manufacturing service for the first half of 2020.
This marks a growth of 26% when compared to the same period in 2019.
The company added that the prior year figures have been adjusted for a market approval milestone by one of its licensees.
For the whole of 2020 the company projects revenue of approximately EUR11.0m, which would exceed last year's revenue record.
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement